Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIPHETAMINE 7.5 vs AZASITE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
Treatment of bacterial conjunctivitis caused by susceptible organisms
Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
6-8 hours (amphetamine moiety), 10-13 hours (dextroamphetamine); clinical effects may outlast serum levels due to accumulation.
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Hepatic metabolism via CYP2D6, deamination, and glucuronidation; major metabolites include 4-hydroxyamphetamine and hippuric acid.
Not significantly metabolized; primarily excreted unchanged in bile and urine.
Renal: ~70-90% unchanged and as active metabolites; minor fecal elimination. Acidic urine (p H <5.6) increases excretion; alkaline urine (p H >7.0) decreases it.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
~16-20%; primarily albumin and alpha-1-acid glycoprotein.
~50-60% bound to plasma proteins (primarily albumin).
4-5 L/kg; extensive tissue distribution with high CNS penetration.
Vd: ~100 L/kg (extensive tissue penetration; not meaningful for topical use; systemic Vd based on IV data).
PO: 75-100% (immediate-release); food delays absorption but does not affect total AUC.
Ophthalmic: negligible systemic absorption (<10% of topical dose) due to low corneal permeability and dilution by tears.
GFR 15-29 m L/min: 50% of normal dose; GFR <15 m L/min: avoid use.
No dosage adjustment required for ophthalmic use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No dosage adjustment required for ophthalmic use.
Children 6-17 years: initial 2.5 mg orally once daily; may increase by 2.5-5 mg weekly; maximum 30 mg daily.
Safety and efficacy in pediatric patients have not been established; limited data available.
Start at 2.5 mg orally once daily; increase by 2.5 mg weekly as tolerated; monitor for cardiovascular effects and insomnia.
No specific dosage adjustment recommended; use same dosing as for adults.
WARNING: ABUSE AND DEPENDENCE. Amphetamines have a high potential for abuse; prolonged use may lead to drug dependence; misuse may cause sudden death or serious cardiovascular events.
None
Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase may occur; monitor for hypertension and tachycardia.,Psychiatric adverse reactions: exacerbation of pre-existing psychosis, mania, aggression, or new psychotic/manic symptoms.,Long-term suppression of growth in children; monitor height and weight.,Seizures: may lower seizure threshold; discontinue if seizures occur.,Peripheral vasculopathy: Raynaud's phenomenon; monitor for digital changes.
Prolonged use may result in overgrowth of nonsusceptible organisms,Contact lens should not be worn during treatment,Do not inject subconjunctivally or introduce into the anterior chamber
Hypersensitivity to amphetamine or other sympathomimetic amines,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Glaucoma,Hyperthyroidism,Moderate to severe hypertension,Advanced arteriosclerosis,Symptomatic cardiovascular disease,History of drug abuse
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,Hypersensitivity to any component of the formulation
Avoid high-fat meals as they may delay absorption. Avoid excessive caffeine intake as it may potentiate stimulant effects and increase anxiety. Ensure adequate hydration to reduce the risk of dry mouth and constipation. No specific foods are contraindicated, but a balanced diet is recommended to mitigate appetite suppression.
No clinically significant food interactions. Administer with or without food as per dosing instructions.
Pregnancy category C. First trimester: possible increased risk of congenital malformations (e.g., cardiac, orofacial clefts) based on limited human data and animal studies. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (including irritability, hyperexcitability). Use only if potential benefit justifies risk.
Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observed in animal studies at doses up to 200 mg/kg/day (systemic). Limited human data; risk is considered low. First trimester: unlikely to cause major malformations. Second and third trimesters: no specific risks identified.
Not recommended. Amphetamine is excreted into breast milk; M/P ratio not established. Potential for infant exposure causing adverse effects such as irritability, poor feeding, and sleep disturbance. American Academy of Pediatrics recommends contraindication.
Azithromycin is excreted into human milk after systemic administration; the M/P ratio is approximately 0.90. After ophthalmic administration, systemic absorption is minimal, resulting in negligible exposure to the infant. Considered compatible with breastfeeding; use with caution if eye drops are applied multiple times daily.
No established dosing guidelines. Pregnancy may alter pharmacokinetics of amphetamines due to increased plasma volume and hepatic metabolism; consider using the lowest effective dose. Monitor clinical response and adjust as needed.
No dose adjustment is necessary for ophthalmic use in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) do not significantly affect topical ocular drug levels due to negligible systemic absorption.
Biphetamine 7.5 is a fixed-dose combination of amphetamine and dextroamphetamine (ratio 1:1) used for ADHD. Monitor for cardiovascular adverse effects including hypertension, tachycardia, and sudden cardiac death, especially in patients with structural cardiac abnormalities. Avoid in patients with a history of drug abuse due to high abuse potential. Use with caution in patients with bipolar disorder as it may induce manic episodes. Assess for growth suppression in pediatric patients during long-term therapy.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic used for bacterial conjunctivitis. Shake well before each use. Avoid contact with contact lenses during treatment. Do not use for more than 14 days. Monitor for signs of hypersensitivity.
Take the medication exactly as prescribed; do not increase the dose or frequency without consulting your doctor.,Avoid taking this medication late in the day to prevent sleep disturbances.,Report any chest pain, shortness of breath, or fainting immediately.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Store in a secure location away from children and others to prevent misuse.,Attend regular follow-ups for blood pressure, heart rate, and growth monitoring (in children).
Shake the bottle well before each use.,Wash hands before and after application.,Do not touch the dropper tip to any surface.,Remove contact lenses before use; do not reinsert during treatment.,Instill the prescribed number of drops in the affected eye(s).,Avoid wearing eye makeup during treatment.,Finish the entire course of medication even if symptoms improve.,Report any worsening, itching, or swelling to your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIPHETAMINE 7.5 vs AZASITE, answered by our medical review team.
BIPHETAMINE 7.5 is a Central Nervous System Stimulant that works by Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.. AZASITE is a Macrolide Antibiotic that works by Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIPHETAMINE 7.5 and AZASITE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIPHETAMINE 7.5 is: Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.. The standard adult dose of AZASITE is: 1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIPHETAMINE 7.5 and AZASITE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIPHETAMINE 7.5 is classified as Category C. Pregnancy category C. First trimester: possible increased risk of congenital malformations (e.g., cardiac, orofacial clefts) based on limited human data and animal studies. Second . AZASITE is classified as Category C. Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.